A diabetes device trial is a research study where people with diabetes test new or improved medical devices before they become widely available to the public. These aren't trials for medications—they're specifically about the physical tools and equipment that help manage blood sugar levels. Companies and research institutions run these trials to gather real-world data about how well devices work, how safe they are, and whether they truly help people live better lives with diabetes.
Learn About Paying Your FGUA Bill Online →
The devices being tested range from continuous glucose monitors (small sensors that track blood sugar around the clock) to insulin pumps (machines that deliver insulin automatically throughout the day) to newer closed-loop systems that work almost like an artificial pancreas. Some trials test refinements to existing devices—like making a sensor smaller, more accurate, or longer-lasting. Other trials introduce entirely new technology that hasn't been tested in humans before.
Here's what makes device trials different from other research: they're intensely practical. Instead of answering questions in a lab setting, researchers want to know how devices perform in real life. How does the monitor work when you're exercising? Does the pump stay accurate over weeks of use? Will the sensor stay attached through showering and sweating? These questions can only be answered by real people living their real lives.
Device trials typically involve several phases. Early-phase trials might include just 20 or 30 people and focus on safety and basic function. Later-phase trials might include hundreds of participants and measure whether the device actually improves health outcomes like blood sugar control or quality of life. A trial might last anywhere from a few months to a couple of years.
Takeaway: Device trials are structured research projects testing real medical equipment in real-world conditions—they're the bridge between laboratory invention and the devices your doctor might eventually prescribe.
Before any diabetes device can be sold in the United States, the FDA (Food and Drug Administration) requires extensive evidence that it's safe and effective. This is where trials come in. Manufacturers cannot simply claim their new insulin pump is better or their glucose sensor is more accurate—they must prove it through rigorous testing with actual human participants. Trials generate the scientific data that regulators review to decide whether to approve a device for public use.
Free Guide to Pay by Plate Illinois Billing →
Device makers are searching for specific information during trials. They want to measure accuracy—does the glucose monitor read correctly compared to lab blood tests? They want to assess reliability—does the device keep working properly over its intended lifespan? They measure user experience—do people find the device intuitive, or do instructions confuse them? They also look for any unexpected side effects or problems that didn't show up in earlier laboratory testing.
Beyond FDA requirements, companies also run trials to stay competitive. The diabetes device market is crowded. A pump manufacturer might test a new infusion set design that's less likely to kink. A glucose monitor company might test a sensor that lasts longer or requires less fingerstick calibrations. A closed-loop system maker might test an algorithm improvement that keeps blood sugar more stable overnight. These trials help companies understand what diabetics actually want and need.
Insurance and healthcare systems also influence trial design. Researchers might measure how much time a device saves during daily management, whether it reduces hospitalizations, or whether it improves long-term health markers. This real-world evidence helps hospitals and insurance plans decide whether to cover a device and how much they'll reimburse for it.
Researchers involved in trials also conduct them because they want to advance the field. Academic medical centers and hospitals often partner with device makers to run trials. These researchers genuinely want to find better tools for their patients and gather knowledge that benefits everyone with diabetes.
Takeaway: Trials happen because regulations require proof, companies compete for better technology, and researchers want genuine improvements—all of which means participants are testing devices that could realistically become mainstream treatments.
The landscape of devices in trial right now covers several major categories. Continuous glucose monitoring (CGM) devices are among the most actively researched. While CGM systems already exist and many people use them, manufacturers continuously test improvements: sensors that work for two weeks instead of one, versions that communicate directly to smartwatches, systems that require less frequent fingerstick checks for calibration, or monitors that work more accurately at extremely high or low blood sugar levels.
Free Guide to Mold Removal Methods for Walls →
Insulin delivery systems—pumps and patch pumps—are another major trial category. Traditional insulin pumps have been around for decades, but researchers test new versions regularly. Current trials might focus on smaller, lighter pumps; pumps with longer battery life; devices with quieter operation; or systems with more user-friendly interfaces. Patch pumps, which stick directly to skin like a large adhesive patch without external tubing, are still being refined and tested in various trial programs.
Closed-loop systems represent the frontier of diabetes technology. Sometimes called "artificial pancreas" systems, these combine a glucose monitor, insulin pump, and computer algorithm that automatically adjusts insulin delivery based on blood sugar readings. Several closed-loop systems are already FDA-approved and on the market, but trials continue testing next-generation versions: systems that work better during exercise, versions that deliver both insulin and glucagon (a medication that raises blood sugar), or algorithms fine-tuned for specific age groups like teenagers or elderly adults.
Beyond the "big three" categories, trials test supporting technologies. This includes new infusion sets (the small tubes that deliver insulin under the skin), better adhesive patches that stick longer without skin irritation, improved lancets for fingerstick blood testing, smartphone apps that integrate with devices, and data management platforms that help patients and doctors track patterns. Some trials test glucagon injection devices or nasal glucagon products designed for emergency low blood sugar situations.
Trials also explore less common but promising technologies: implantable glucose sensors that sit under the skin for months, artificial intelligence systems that predict blood sugar trends hours in advance, devices that deliver medications through the skin without needles, and wearable patches that do multiple functions simultaneously. Early-stage trials for these emerging technologies help determine whether they're safe and practical enough to pursue further development.
Takeaway: Device trials aren't just testing completely new ideas—many test improvements to devices you might already know about, plus genuinely novel technology on the horizon that could transform diabetes management.
Finding diabetes device trials requires knowing where to look. ClinicalTrials.gov is the official U.S. registry where researchers must list virtually all clinical trials. You can visit the website directly and search for trials by condition (type 1 diabetes, type 2 diabetes), device type (glucose monitor, insulin pump), and location. The site shows trial phases, what participation involves, and contact information for researchers. Hospital websites and major medical centers often list ongoing trials on their research pages. Universities with endocrinology programs frequently conduct device trials and post information on their diabetes research websites.
How to Delete Your Fitbit Account Guide →
Device manufacturers' websites sometimes describe active trials, though the information may be scattered across research sections or news pages. The American Diabetes Association publishes trial information and periodically updates listings of current studies. Smaller organizations focused on specific diabetes types or specific devices may also maintain trial databases relevant to their communities.
Understanding what a trial actually involves requires reading beyond the title. Each trial has a detailed protocol—a document describing exactly what participation means. Will you visit a research office monthly or just a few times? Will you need to do extra fingerstick tests to provide comparison data? Will you wear additional devices for monitoring purposes? Some trials are low-burden (maybe one visit and a phone survey), while others require significant time and commitment. The protocol explains testing requirements, data collection methods, visits needed, and how long participation lasts.
Trial descriptions also explain inclusion and exclusion criteria. Some trials might focus specifically on children, teenagers, adults, or people over 65—not because the device won't work for others, but because the research question applies to that age group. Some trials require people to have certain types of insurance or to live within a certain distance of the research site. Others might require stable blood sugar control before enrollment, or conversely, might specifically recruit people whose blood sugar is difficult to control. These criteria exist for scientific reasons, not arbitrarily.
You'll encounter terms like "randomized" (some participants get the new device, others get standard care or the current best device) or "open-label" (everyone gets the new device). Some trials are double-blind, meaning neither participants nor researchers know which treatment each person is receiving (used mainly when comparing medications, less common with devices). Understanding the trial design helps you
This guide is for general information only and is not medical, financial, legal, or other professional advice. For decisions specific to your situation, consult a qualified professional. See our Editorial Policy.